Skip to content

DW Evaluation of Lotrafilcon B Lenses in a Modified Design

Daily Wear (DW) Evaluation of Lotrafilcon B in a Modified Design

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02157909
Enrollment
134
Registered
2014-06-06
Start date
2014-06-30
Completion date
2014-07-31
Last updated
2015-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Keywords

Lens fit, contact lenses, myopia

Brief summary

The purpose of this study is to demonstrate that Lotrafilcon B AIR OPTIX® AQUA sphere modified design lenses are noninferior to Lotrafilcon B AIR OPTIX® AQUA in overall lens fit by comparing the percent of subjects satisfying the no re-fit criteria in each treatment group.

Interventions

DEVICELotrafilcon B sphere modified design contact lenses
DEVICELotrafilcon B sphere contact lenses

Sponsors

Alcon Research
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Must sign an Informed Consent Document; * Myopic, wear AIR OPTIX® AQUA lenses in the range of -1.00 to -5.00 diopters (D) in both eyes, and willing to comply with the wearing schedule; * Manifest cylinder less than or equal to 0.75 D; * Able to achieve best corrected visual acuity (BCVA) of 20/25 (Snellen) or better in each eye at distance; * Able to achieve distance visual acuity of at least 20/40 in each eye with habitual and study lenses; * Wearing spherical AIR OPTIX® AQUA lenses in both eyes for at least 3 months (at least 8 hours per day, at least 5 days per week), wearing the habitual lenses for a minimum of 4 hours prior to the baseline study visit, and achieving an acceptable or optimal fit at baseline visit with habitual lenses in both eyes; * Other protocol-defined criteria may apply.

Exclusion criteria

* Current soft contact lens wearer who regularly sleeps in lenses (1 or more nights per week); * Any anterior segment infection, inflammation, disease, or abnormality that contraindicates contact lens wear within 6 months prior to enrollment; * Any use of systemic or ocular medications for which contact lens wear could be contraindicated including any use of topical ocular medications that would require instillation during contact lens wear; * History of herpetic keratitis; * History of corneal or refractive surgery or irregular cornea; * A pathologically dry eye that precludes contact lens wear; * Monocular (only one eye with functional vision); * Monovision correction; * History of intolerance or hypersensitivity to any component of the test articles or associated materials; * Concurrent participation in a contact lens or contact lens care product clinical trial or within the previous 30 days; * Eye injury or ocular or intra-ocular surgery within 6 months prior to enrollment; * Any ocular or systemic medical condition that may, in the opinion of the investigator, preclude safe administration of the study lenses or affect the results of this study; * Other protocol-defined

Design outcomes

Primary

MeasureTime frameDescription
Proportion of Subjects Satisfying the 'no Re-fit' Criteria in Both EyesDispense (Day 0), Week 1With the contact lens on eye, the investigator assessed the lens fit immediately post-blink and following lower lid margin push-up with the lower lid using a 5-point scale, where -2 = Unacceptably tight (reduced movement, unacceptable), -1 = Acceptably tight (reduced movement, acceptable), 0 = Optimal fit / movement, +1 = Acceptably loose (excessive movement, acceptable), and +2 = Unacceptably loose (excessive movement, unacceptable). To meet the definition of no re-fit, an eye had to have an acceptable or optimal overall lens fit with the study lens, as well as be within 1 grade of the overall lens fit assessed with the habitual lens at baseline. Proportion of subjects is reported as a percentage.

Participant flow

Recruitment details

Subjects were recruited from 5 study centers located in the US.

Pre-assignment details

Of the 134 enrolled, 2 subjects were exited as screen failures prior to randomization. This reporting group includes all randomized subjects (132).

Participants by arm

ArmCount
AOA Modified
Modified design contact lenses worn at least 8 hours per day, 5 days per week on a daily wear basis for 7 days
66
AOA Sphere
Sphere contact lenses worn at least 8 hours per day, 5 days per week on a daily wear basis for 7 days
66
Total132

Baseline characteristics

CharacteristicAOA ModifiedAOA SphereTotal
Age, Continuous29.9 years
STANDARD_DEVIATION 9.5
31.3 years
STANDARD_DEVIATION 9.8
30.6 years
STANDARD_DEVIATION 9.6
Sex: Female, Male
Female
45 Participants50 Participants95 Participants
Sex: Female, Male
Male
21 Participants16 Participants37 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —
other
Total, other adverse events
0 / 1340 / 660 / 66
serious
Total, serious adverse events
0 / 1340 / 660 / 66

Outcome results

Primary

Proportion of Subjects Satisfying the 'no Re-fit' Criteria in Both Eyes

With the contact lens on eye, the investigator assessed the lens fit immediately post-blink and following lower lid margin push-up with the lower lid using a 5-point scale, where -2 = Unacceptably tight (reduced movement, unacceptable), -1 = Acceptably tight (reduced movement, acceptable), 0 = Optimal fit / movement, +1 = Acceptably loose (excessive movement, acceptable), and +2 = Unacceptably loose (excessive movement, unacceptable). To meet the definition of no re-fit, an eye had to have an acceptable or optimal overall lens fit with the study lens, as well as be within 1 grade of the overall lens fit assessed with the habitual lens at baseline. Proportion of subjects is reported as a percentage.

Time frame: Dispense (Day 0), Week 1

Population: This analysis population includes all randomized and treated subjects.

ArmMeasureGroupValue (NUMBER)
AOA ModifiedProportion of Subjects Satisfying the 'no Re-fit' Criteria in Both EyesDispense (Day 0)100.0 percentage of subjects
AOA ModifiedProportion of Subjects Satisfying the 'no Re-fit' Criteria in Both EyesWeek 1100.0 percentage of subjects
AOA SphereProportion of Subjects Satisfying the 'no Re-fit' Criteria in Both EyesDispense (Day 0)100.0 percentage of subjects
AOA SphereProportion of Subjects Satisfying the 'no Re-fit' Criteria in Both EyesWeek 1100.0 percentage of subjects

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026